Diurnal Variation of Hypothalamic Function and Chronic Subthalamic Nucleus Stimulation in Parkinson's DiseaseSeifried C.a · Boehncke S.b · Heinzmann J.a · Baudrexel S.a · Weise L.c · Gasser T.d · Eggert K.e · Fogel W.f · Baas H.g · Badenhoop K.b · Steinmetz H.a · Hilker R.a
Departments of aNeurology, bEndocrinology, and cNeurosurgery, Goethe University Frankfurt am Main, Frankfurt am Main, dDepartment of Neurosurgery, University of Essen, Essen, eDepartment of Neurology, Philipps University Marburg, Marburg, fDeutsche Klinik für Diagnostik Wiesbaden, Wiesbaden, and gKlinikum Hanau, Hanau, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Deep brain stimulation of the subthalamic nucleus (STN-DBS) improves quality of life in patients with advanced Parkinson's disease (PD), but is associated with neuropsychiatric side effects and weight gain in some individuals. The pathomechanisms of these phenomena are still unknown. Considering anatomical and functional connections of the STN with the hypothalamic-pituitary (HP) system, we prospectively investigated whether chronic STN-DBS alters HP functioning in 11 PD patients. Methods: Basal hormone levels of the HP-adrenal (HPA), HP-gonadal and HP-somatotropic axis were determined before surgery as well as 3 and 6 months after electrode implantation. In addition, 24-hour cortisol profiles and dexamethasone suppression tests were obtained. Postoperative hormone changes were correlated with individual neuropsychological test performance, psychiatric status and anthropometric measures. Results: While PD patients experienced weight gain (p = 0.025) at follow-up, most neuropsychological data and basal HP hormone levels did not change over time. HPA regulation and diurnal rhythmicity of cortisol remained intact in all patients. The 24-hour mean cortisol levels decreased 6 months after surgery (p = 0.002) correlating with improved postoperative depression (p = 0.02). Conclusions: Chronic application of high-frequency electrical stimuli in the STN was not associated with HP dysfunction in patients with advanced PD. The diurnal variability of peripheral cortisol secretion as one important element of the endogenous biological clock remained intact. Evening cortisol levels decreased after surgery reflecting a favorable regulation of the cortisol setpoint. STN-DBS can be considered safe from a neuroendocrine perspective, but the origin of unwanted side effects warrants further elucidation.
© 2012 S. Karger AG, Basel
- Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P: Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-1934.
- Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, Daniels C, Deutschlander A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J: A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
- Drapier D, Drapier S, Sauleau P, Haegelen C, Raoul S, Biseul I, Peron J, Lallement F, Rivier I, Reymann JM, Edan G, Verin M, Millet B: Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol 2006;253:1083-1091.
- Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach M, D'Ambrosia J, Thobois S, Tamma F, Herzog J, Speelman JD, Samanta J, Kubu C, Rossignol H, Poon YY, Saint-Cyr JA, Ardouin C, Moro E: A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008;131:2720-2728.
- Temel Y: Limbic effects of high-frequency stimulation of the subthalamic nucleus. Vitam Horm 2010;82:47-63.
- Barichella M, Marczewska AM, Mariani C, Landi A, Vairo A, Pezzoli G: Body weight gain rate in patients with Parkinson's disease and deep brain stimulation. Mov Disord 2003;18:1337-1340.
- Montaurier C, Morio B, Bannier S, Derost P, Arnaud P, Brandolini-Bunlon M, Giraudet C, Boirie Y, Durif F: Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation. Brain 2007;130:1808-1818.
- McIntyre CC, Hahn PJ: Network perspectives on the mechanisms of deep brain stimulation. Neurobiol Dis 2010;38:329-337.
- Temel Y, Blokland A, Steinbusch HW, Visser-Vandewalle V: The functional role of the subthalamic nucleus in cognitive and limbic circuits. Prog Neurobiol 2005;76:393-413.
- Swaab DF, Bao AM, Lucassen PJ: The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005;4:141-194.
- Pereira AM, Tiemensma J, Romijn JA: Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology 2010;92(suppl 1):65-70.
- Dimopoulou C, Ising M, Pfister H, Schopohl J, Stalla GK, Sievers C: Increased prevalence of anxiety associated personality traits in patients with Cushing's disease: a cross-sectional study. Neuroendocrinology 2012, E-pub ahead of print.
- Bjorntorp P: Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2001;2:73-86.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
- Seifried C, Weise L, Hartmann R, Gasser T, Baudrexel S, Szelenyi A, van de Loo S, Steinmetz H, Seifert V, Roeper J, Hilker R: Intraoperative microelectrode recording for the delineation of subthalamic nucleus topography in Parkinson's disease. Brain Stimulation 2012;5:378-387.
- Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the apathy evaluation scale. Psychiatry Res 1991;38:143-162.
- Sahin M, Kebapcilar L, Taslipinar A, Azal O, Ozgurtas T, Corakci A, Akgul EO, Taslipinar MY, Yazici M, Kutlu M: Comparison of 1 mg and 2 mg overnight dexamethasone suppression tests for the screening of Cushing's syndrome in obese patients. Intern Med 2009;48:33-39.
- Posener JA, DeBattista C, Williams GH, Chmura Kraemer H, Kalehzan BM, Schatzberg AF: 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 2000;57:755-760.
- Agid O, Kohn Y, Lerer B: Environmental stress and psychiatric illness. Biomed Pharmacother 2000;54:135-141.
- Jezova D, Hlavacova N: Endocrine factors in stress and psychiatric disorders: focus on anxiety and salivary steroids. Ann NY Acad Sci 2008;1148:495-503.
- Binder EB, Nemeroff CB: The CRF system, stress, depression and anxiety - insights from human genetic studies. Mol Psychiatry 2010;15:574-588.
- Montgomery EB Jr, Baker KB: Mechanisms of deep brain stimulation and future technical developments. Neurol Res 2000;22:259-266.
- Ballanger B, Jahanshahi M, Broussolle E, Thobois S: Pet functional imaging of deep brain stimulation in movement disorders and psychiatry. J Cereb Blood Flow Metab 2009;29:1743-1754.
- Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K: Optical deconstruction of parkinsonian neural circuitry. Science 2009;324:354-359.
- Li S, Arbuthnott GW, Jutras MJ, Goldberg JA, Jaeger D: Resonant antidromic cortical circuit activation as a consequence of high-frequency subthalamic deep-brain stimulation. J Neurophysiol 2007;98:3525-3537.
- Nauta HJ, Cole M: Efferent projections of the subthalamic nucleus: an autoradiographic study in monkey and cat. J Comp Neurol 1978;180:1-16.
- Haber SN, Groenewegen HJ, Grove EA, Nauta WJ: Efferent connections of the ventral pallidum: evidence of a dual striato pallidofugal pathway. J Comp Neurol 1985;235:322-335.
- Coenen VA, Schlaepfer TE, Maedler B, Panksepp J: Cross-species affective functions of the medial forebrain bundle-implications for the treatment of affective pain and depression in humans. Neurosci Biobehav Rev 2011;35:1971-1981.
- Coenen VA, Honey CR, Hurwitz T, Rahman AA, McMaster J, Burgel U, Madler B: Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson's disease. Neurosurgery 2009;64:1106-1114.
- Challet E: Entrainment of the suprachiasmatic clockwork in diurnal and nocturnal mammals. Endocrinology 2007;148:5648-5655.
- Kalsbeek A, van der Spek R, Lei J, Endert E, Buijs RM, Fliers E: Circadian rhythms in the hypothalamo-pituitary-adrenal axis. Mol Cell Endocrinol 2012;349:20-29.
- Herzog ED, Takahashi JS, Block GD: Clock controls circadian period in isolated suprachiasmatic nucleus neurons. Nat Neurosci 1998;1:708-713.
- Buijs RM, Scheer FA, Kreier F, Yi C, Bos N, Goncharuk VD, Kalsbeek A: Organization of circadian functions: interaction with the body. Prog Brain Res 2006;153:341-360.
- Panda S, Hogenesch JB, Kay SA: Circadian rhythms from flies to human. Nature 2002;417:329-335.
- Reppert SM, Weaver DR: Coordination of circadian timing in mammals. Nature 2002;418:935-941.
- Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I: Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging 1997;18:285-289.
- Tsigos C, Chrousos GP: Physiology of the hypothalamic-pituitary-adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol Metab Clin North Am 1994;23:451-466.
- Gold PW, Goodwin FK, Chrousos GP: Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress. 2. N Engl J Med 1988;319:413-420.
- Gold PW, Goodwin FK, Chrousos GP: Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress. 1. N Engl J Med 1988;319:348-353.
- Muller T, Muhlack S: Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease. Clin Neuropharmacol 2007;30:101-106.
- Sauleau P, Leray E, Rouaud T, Drapier S, Drapier D, Blanchard S, Drillet G, Peron J, Verin M: Comparison of weight gain and energy intake after subthalamic versus pallidal stimulation in Parkinson's disease. Mov Disord 2009;24:2149-2155.
- Temel Y, Boothman LJ, Blokland A, Magill PJ, Steinbusch HW, Visser-Vandewalle V, Sharp T: Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. Proc Natl Acad Sci USA 2007;104:17087-17092.
- Tan SK, Hartung H, Visser-Vandewalle V, Steinbusch HW, Temel Y, Sharp T: A combined in vivo neurochemical and electrophysiological analysis of the effect of high-frequency stimulation of the subthalamic nucleus on 5-HT transmission. Exp Neurol 2012;233:145-153.
- Tan SK, Hartung H, Sharp T, Temel Y: Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus? Neuropharmacology 2011;61:387-399.
- Escamilla-Sevilla F, Perez-Navarro MJ, Munoz-Pasadas M, Saez-Zea C, Jouma-Katati M, Piedrola-Maroto G, Ramirez-Navarro A, Minguez-Castellanos A: Change of the melanocortin system caused by bilateral subthalamic nucleus stimulation in Parkinson's disease. Acta Neurol Scand 2011;124:275-281.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.